CORRECT: Oxford BioMedica to acquire 80% ownership of new US business
CORRECT: Oxford BioMedica to acquire 80% ownership of new US business
Read moreCORRECT: Oxford BioMedica to acquire 80% ownership of new US business
Read moreLONDON MARKET MIDDAY: Stocks sink on Ukraine tensions and hawkish Fed
Read moreOxford BioMedica to acquire 80% ownership of new US virus business
Read more(Sharecast News) - Cell and gene therapy specialist Oxford Biomedica announced an agreement with Homology Medicines on Friday, as well as a placing to raise £80m from new and existing shareholders, including a retail offer through the PrimaryBid platform.
Read moreOxford Biomedica starts search for new CEO as Dawson steps down
Read more(Sharecast News) - Oxford Biomedica chief executive John Dawson said he was stepping down after 13 years at the helm of the Gene and cell therapy firm which helped develop a Covid-19 vaccine with AstraZeneca.
Read moreOxford Biomedica wins new agreement for LentiVector platform
Read more(Sharecast News) - Gene and cell therapy group Oxford Biomedica on Wednesday said it had signed a new license and supply agreement on its LentiVector platform with US-based Cabaletta Bio.
Read moreLONDON BROKER RATINGS: BofA starts Pod Point at Buy; Barclays cuts DCC
Read moreOxford Biomedica in license and supply deals with Novartis and Arcellx
Read more(Sharecast News) - Gene and cell therapy group Oxford Biomedica has struck new license and supply agreements for its lentiviral vectors.
Read moreOxford BioMedica licences technology for cystic fibrosis treatment
Read more(Sharecast News) - Gene and cell therapy firm Oxford Biomedica said on Tuesday that pharmaceutical giant Boehringer Ingelheim had exercised its option to license its lentiviral vector technology to manufacture, register and commercialise a treatment for cystic fibrosis.
Read moreLONDON BROKER RATINGS: Keppler Cheuvreux raises Pearson to Hold
Read moreLONDON BROKER RATINGS: Investec prefers 888 over Entain
Read more